Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA

Law360, New York (March 21, 2011, 1:57 PM EDT) -- Mylan Pharmaceuticals Inc. is accusing the U.S. Food and Drug Administration of stalling on a decision that could give Ranbaxy Laboratories Ltd. exclusive rights to market a generic version of the cholesterol drug Lipitor, saying the delay could cost patients millions of dollars.

Mylan, which also wants to make a generic version of Lipitor, filed its lawsuit Friday in the U.S. District Court for the District of Columbia. It asks the court to require the FDA to strip India-based Ranbaxy of its eligibility for the exclusive...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.